{"name":"Hammond, H. Kirk, M.D.","slug":"hammond-h-kirk-m-d","ticker":"","exchange":"","domain":"","description":"Hammond, H. Kirk, M.D. is a biotechnology company focused on developing innovative therapies. The company has a marketed product, Sucrose (3%), and previously worked on Ad5.hAC6, which was discontinued.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Sucrose (3%)","genericName":"Sucrose (3%)","slug":"sucrose-3","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"Sucrose (3%)","genericName":"Sucrose (3%)","slug":"sucrose-3","phase":"marketed","mechanism":"Sucrose 3% acts as an osmotic agent and sweetening excipient that may provide mild osmotic laxative effects and serve as a vehicle or stabilizer in pharmaceutical formulations.","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}